TICKERNERD
Menu
APLMAPLMHealthcare · Biotechnology

APLM Stock Forecast: Apollomics, Inc. Price Predictions for 2026-2027

Last close, 21 Aug 2026
$23
−0.81% on the day

Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 16 of 100 as at 22 Aug 2026 — in the weakest quartile.

Market cap
$70.5M
Ticker Nerd rank
16 / 100
Median analyst target
—
Analysts covering
0
Total return, dividends reinvested
1W
−0.1%
1M
+25.0%
YTD
+25.1%
1Y
+286.4%
From 52W high
−36.2%
From 52W low
+494.6%
$4
$37
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

APLM stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Apollomics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
16 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
82
Momentum
69
Issuance
42
Accruals
34
Volatility
27
Revisions
25
Growth
23
Value
14
Quality
3

Size (82): Smaller than most of the companies we track.

Quality (3): Profits are thin or unreliable for the size of the business, or they are not turning into cash.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

APLM stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on APLM, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$10$20$30$40Oct 25Jan 26Apr 26Jul 26APLM

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
8 May 2024HC Wainwright & Co.MaintainsBuy$5.00 → $2.00
1 Apr 2024EF HuttonMaintainsBuy—
1 Apr 2024HC Wainwright & Co.MaintainsBuy—
20 Nov 2023HC Wainwright & Co.ReiteratesBuy—
3 Oct 2023HC Wainwright & Co.MaintainsBuy—
23 Aug 2023EF HuttonAssumesBuy$25
5 June 2023HC Wainwright & Co.ReiteratesBuy—
1 June 2023HC Wainwright & Co.InitiatesBuy—
25 May 2023EF HuttonAssumesBuy$25
25 Apr 2023EF HuttonInitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. APLM appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

APLM analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Fundamentals

Apollomics, Inc. (APLM) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
8.0×

Cheaper than 17% of US stocks

Price / book
−98.5×

Cheaper than 99% of US stocks

EV / EBITDA
−5.4×

Cheaper than 79% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
431.9%

Higher than 99% of US stocks

Net margin
−123.7%

Higher than 5% of US stocks

Returns & dividend
Return on equity
−1305.4%

Higher than 1% of US stocks

Return on assets
−57.6%

Higher than 7% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

APLM vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
APLMApollomics, Inc.$70.5M
16
TILInstil Bio, Inc.$51.4M
50
TCRXTScan Therapeutics, Inc.$50.9M
37
NTRBNutriband, Inc.$56.2M
19
IBOImpact BioMedical, Inc.$50.2M
24
ATYRaTyr Pharma, Inc.$49.2M
51
HRTXHeron Therapeutics, Inc.$58.3M
44

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Apollomics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest APLM news & analysis

Apollomics Announces $10 Million Private Placement Transaction

GlobeNewsWire · 11 Aug 2026neutral

Apollomics Inc. announced it has entered into definitive subscription agreements for a private placement with accredited investors, expecting aggregate gross proceeds of approximately $10.0 million. The transaction is expected to close on or about August 14, 2026, subject to customary closing conditions.

Why it matters — A $10 million private placement would provide Apollomics with additional capital to support its late-stage oncology drug development programs.

FAQ

Frequently asked questions about APLM stock

How does Ticker Nerd's model rank APLM?

As at 22 Aug 2026, Apollomics, Inc. ranks 16 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (82 of 100).

What is the APLM stock forecast for 2030?

No analyst covering Apollomics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for APLM are extrapolating price history, which says nothing about the business.

How has APLM stock performed over the past year?

Apollomics, Inc. returned +286.4% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Apollomics, Inc. do?

Apolomics Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies.

What is the latest news on APLM?

The most recent item we track (GlobeNewsWire, 11 Aug 2026): "Apollomics Announces $10 Million Private Placement Transaction". Apollomics Inc. announced it has entered into definitive subscription agreements for a private placement with accredited investors, expecting aggregate gross proceeds of approximately $10.0 million. The transaction is expected to close on or about August 14, 2026, subject to customary closing conditions.

Company

About Apollomics, Inc.

Apolomics Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies. It specializes in innovative product candidates designed to harness the immune system and target specific molecular pathways to inhibit cancer, with potential for combination with other treatment options. The company's pipeline includes late-stage clinical assets such as vebreltinib (APL-101), a potent, selective c-Met inhibitor for non-small cell lung cancer and other advanced tumors with c-Met alterations, currently in Phase 2 trials, and uproleselan (APL-106), an E-Selectin antagonist for use with chemotherapy in acute myeloid leukemia and hematologic cancers, in Phase 1 and Phase 3 trials in China. Additional candidates like APL-102, a multiple tyrosine kinase inhibitor, are in early clinical stages. Apolomics Inc. addresses unmet medical needs in difficult-to-treat cancers through its broad portfolio across multiple oncology programs. Founded in 2015 and headquartered in Foster City, California, with operations extending to Taipei, Taiwan, the company operates under the guidance of experienced leadership in biotechnology and pharmaceuticals.

CEO Mr. Hung-Wen Chen · 14 employees · United States · https://www.apollomicsinc.com